Actinium (ATNM) Director Jeffrey W. Chell Receives RSU and Option Awards

What Happened

• Jeffrey W. Chell, a director of Actinium Pharmaceuticals (ATNM), received two grant awards reported on a Form 4 dated 2026-09-04 for transactions on 2026-09-02: 61,600 restricted stock units (RSUs) acquired at $0 and 92,400 derivative awards (granted at $0). The filing shows $0 purchase price for both awards (typical for RSU/option grants).

Key Details

• Transaction date(s): 2026-09-02; Form 4 filed: 2026-09-04 (within the standard 2-business-day reporting window).
• Grants and amounts: 61,600 RSUs (grant at $0) and 92,400 derivative awards (grant at $0).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 = the 61,600 RSUs vest 1/3 on each of the first three anniversaries of the grant. F2 = the 92,400 derivative awards are stock options that vest in fifty equal monthly tranches beginning on the grant date.
• Filing timeliness: Report appears timely (filed two days after the transaction date).

Context

• These are awards (grant events), not open‑market purchases or sales. RSUs convert to shares as they vest; the derivative awards described are options that vest monthly — neither represents an immediate cash purchase or sale. Awards to directors are common as compensation and do not by themselves indicate insider sentiment.